Lpath Inc fka LPTN

[My4ntoy]

A bit more info LPTN

Another company that may be in line to receive an offer before the approval process is complete is Lpath Inc. (LPTN). Considering the potential catalysts in play and a prime-time partnership with Pfizer (PFE), Lpath shares may be undervalued right now.

Lpath has become a recognized leader in the field of developing lipid-based therapies through its proprietary ImmuneY2 platform, which contains the ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to the spreading and growth of various diseases and inflammatory/auto-immune disorders. The market potential for this technology in treating a plethora of modern day illnesses and diseases, should it advance past the clinical stages, is huge. Lpath is first applying this technology to treat Wet AMD and cancer, both multi-billion dollar markets, and that could just be the beginning.

http://www.pharmanewswire.com/?prID=94425